Loading stock data…
LTRN
$2.12+0.07 (+3.41%)
Market ClosedLast close May 1
Lantern Pharma Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lantern Pharma Inc. in the Healthcare sector is trading at $2.12. The stock is currently 63% below its 52-week high of $5.74, remaining 38.2% below its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why LTRN maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.12
Potential Upside
5%
Whystock Fair Value$2.23
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$20.00+843.4%
Range$15.00 – $25.00
Fundamentals
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma;...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.16M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.75
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-262.00%
Volume
Today's trading volume
259,274
Recent News
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
Lantern Pharma Inc (LTRN) showcases clinical progress and AI-driven innovations while addressing funding needs and operational hurdles.
Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition
Lantern Pharma, Inc. (NASDAQ:LTRN) is one of the best AI penny stocks to buy right now. On January 20, the FDA granted Lantern Pharma, Inc.’s (NASDAQ:LTRN) LP-284 an Orphan Drug Designation (ODD). LP-284 is an investigational small-molecule therapy for treating soft tissue sarcomas. According to Lantern Pharma, the ODD designation applies in the United States […]
Lantern Pharma (NASDAQ:LTRN) Will Have To Spend Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
FDA clears Starlight Therapeutics’ IND for Phase Ib/IIa glioblastoma trial
The trial aims to assess the tolerability, preliminary efficacy, and safety of the combination therapy in individuals with recurrent GBM.
Lantern Pharma concludes patient enrolment for trial of LP-300 in Japan
The trial is designed to assess the safety and efficacy of LP-300 in never-smoker NSCLC patients.